Dovobet Gel is a topical treatment designed for adults with scalp psoriasis and mild to moderate plaque psoriasis on other body areas. The gel contains two active ingredients: calcipotriol, a vitamin D analog that helps normalize skin cell growth, and betamethasone, a corticosteroid that reduces inflammation.

Please note

This treatment is available only after a consultation with our pharmacist via a private service, called PGD (Patient Group Direction).

A picture of the affected area may facilitate and speed up the processing of your order. This can be sent to pharmacy@medino.com before or after you place the order.

It might be necessary to confirm the identity of the intended user through a verification process.

Please read the Patient information leaflet before starting the treatment.

Over The Counter (OTC)

Ingredients

Active ingredients: 1 gram contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).

Excipient with known effect:

Butylhydroxytoluene (E321) 160 micrograms/g gel

Read the patient leaflet for the full list of ingredients.

Usage and Instructions

Adults: Apply thinly to the affected area once daily for up to 4 weeks. Leave it on the skin all day/night before bathing/showering. For the scalp a teaspoon size is sufficient. Do not use more than 15g daily. Shake the bottle before use. Wash your hands before and after use. Avoid sunlight exposure.

Warnings

Dovobet is contraindicated in:

Under 18 years old
Pregnancy and breastfeeding
Erythrodermic, exfoliative and pustular psoriasis
Calcium metabolism disorders
Viral (e.g. herpes or varicella) lesions of the skin
Fungal or bacterial skin infections
Parasitic infections
Tuberculosis
Perioral dermatitis
Atrophic skin
Striae atrophicae
Fragility of skin veins
Ichthyosis
Acne vulgaris
Acne rosacea
Rosacea
Ulcers and wounds

Warnings:

Effects on endocrine system: Dovobet gel has a strong steroid; concurrent use with other steroids can lead to systemic side effects due to absorption.

Visual disturbance: Systemic and topical corticosteroids may cause visual issues like blurred vision, cataract, or glaucoma.

Effects on calcium metabolism: Exceeding the recommended dose of Dovobet can result in high calcium levels in the blood, which normalizes after discontinuation.

Local adverse reactions: Dovobet contains a strong steroid that shouldn't be applied on sensitive areas; washing hands post-application prevents accidental transfers.

Concomitant skin infections: If skin infections worsen due to Dovobet, cease corticosteroid treatment.

Discontinuation of treatment: Stopping topical corticosteroid use for psoriasis may have risks; medical oversight is important post-treatment.

Long-term use: Prolonged use increases the risk of adverse reactions; discontinue if side effects appear.

Unevaluated use: Dovobet's effect on guttate psoriasis is unknown.

Concurrent treatment and UV exposure: Limited data on combining Dovobet with other treatments; excessive UV exposure should be limited during Dovobet treatment.

Adverse reactions to excipients: Dovobet gel's excipient can cause skin reactions or eye and mucous membrane irritation.

Avoid contact with textiles that can be easily stained by grease, such as silk

Side Effects

Category	Frequency	Condition/Issue
Infections and infestations	Uncommon	Skin infection*
		Folliculitis
Immune system disorders	Rare	Hypersensitivity
Eye disorders	Uncommon	Eye irritation
	Not known	Vision, blurred**
Skin and subcutaneous tissue disorders	Common	Pruritus
	Uncommon	Exacerbation of psoriasis
		Dermatitis
		Erythema
		Rash***
		Acne
		Skin burning sensation
		Skin irritation
		Dry skin
	Rare	Skin striae
		Skin exfoliation
	Not known	Hair colour changes****
General disorders and administration site conditions	Uncommon	Application site pain*****
	Rare	Rebound effect

Notes:
*Skin infections including bacterial, fungal and viral skin infections have been reported.
**See section 4.4.
***Various types of rash reactions such as rash erythematous and rash pustular have been reported.
****Transient discolouration of the hair at scalp application site, to a yellowish colour in white or grey hair, has been reported.
*****Application site burning is included in application site pain.